首页|HBV相关慢加急性肝衰竭患者血清HMGB1、sCD163、PGE2的表达水平及其对预后的预测价值

HBV相关慢加急性肝衰竭患者血清HMGB1、sCD163、PGE2的表达水平及其对预后的预测价值

扫码查看
目的 观察HBV相关慢加急性肝衰竭(HBV-ACLF)患者血清高迁移率族蛋白B1(HMGB1)、可溶性CD163(sCD163)、前列腺素E2(PGE2)的表达水平,并评估三者单独及联合检测对预后的预测价值.方法 收集2022年7月1日—2023年9月30日在新乡医学院第一附属医院感染内科住院的HBV-ACLF患者76例,根据28天预后情况,将其分为生存组(n=48)和死亡组(n=28).收集患者一般资料,计算MELD评分,并采用ELISA法检测血清HMGB1、sCD163和PGE2水平.正态分布的计量资料两组间比较采用成组t检验,非正态分布的计量资料两组间比较采用Mann-Whitney U检验;计数资料两组间比较采用χ2检验.采用Spearman秩相关性分析HMGB1、sCD163和PGE2与MELD评分的相关性;采用受试者工作特征曲线(ROC曲线)分析HMGB1、sCD163和PGE2单独及联合检测对HBV-ACLF患者预后的预测价值.结果 生存组和死亡组间TBil、WBC、中性粒细胞百分数、降钙素原、血清淀粉样蛋白A、IL-6、血清钠(Na+)、血清肌酐(SCr)差异均有统计学意义(P值均<0.05).死亡组血清HMGB1(Z=-2.997,P=0.003)、sCD163(Z=-2.972,P=0.003)和MELD评分(t=-6.997,P<0.001)显著高于生存组,差异均有统计学意义;死亡组血清PGE2水平显著低于生存组,差异有统计学意义(Z=-4.909,P<0.001).Spearman秩相关性分析发现,HMGB1、sCD163与MELD评分呈正相关(r值分别为0.431、0.319,P值均<0.05),PGE2与MELD评分呈负相关(r=-0.412,P<0.001).ROC曲线分析发现,HMGB1、sCD163和PGE2单独预测的曲线下面积(AUC)分别为0.717、0.716、0.856,三者联合预测价值最高,AUC为0.930,敏感度为0.778,特异度为0.920.结论 血清HMGB1、sCD163、PGE2单独及联合检测在预测HBV-ACLF患者预后方面均具有良好参考价值,三者联合预测价值最高,值得进一步观察和研究.
Expression levels of serum high-mobility group box 1,soluble CD163,and prostaglandin E2 in patients with hepatitis B virus-related chronic-on-acute liver failure and their value in predicting prognosis
Objective To investigate the expression levels of serum high-mobility group box 1(HMGB1),soluble CD163(sCD163),and prostaglandin E2(PGE2)in patients with hepatitis B virus-related chronic-on-acute liver failure(HBV-ACLF),and to evaluate the value of the three indicators used alone or in combination in predicting prognosis.Methods A total of 76 patients with HBV-ACLF who were hospitalized in Department of Infectious Diseases,The First Affiliated Hospital of Xinxiang Medical University,from July 1,2022 to September 30,2023 were enrolled,and according to the 28-day prognosis,they were divided into survival group with 48 patients and death group with 28 patients.General data were collected,Model for End-Stage Liver Disease(MELD)score was calculated,and ELISA was used to measure the serum levels of HMGB1,sCD163,and PGE2.The independent-samples t test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups;the chi-square test was used for comparison of categorical data between two groups.The Spearman rank correlation test was used to analyze the correlation of HMGB1,sCD163,and PGE2 with MELD score;the receiver operating characteristic(ROC)curve was used to analyze the value of HMGB1,sCD163,and PGE2 used alone or in combination in predicting the prognosis of HBV-ACLF patients.Results There were significant differences between the two groups in total bilirubin,white blood cell count,the percentage of neutrophils,procalcitonin,serum amyloid A,interleukin-6,serum sodium,and serum creatinine(all P<0.05).Compared with the survival group,the death group had significantly higher serum levels of HMGB1(Z=-2.997,P=0.003)and sCD163(Z=-2.972,P=0.003),a significantly higher MELD score(t=-6.997,P<0.001),and a significantly lower serum level of PGE2(Z=-4.909,P<0.001).The Spearman rank correlation test showed that HMGB1 and sCD163 were positively correlated with MELD score(r=0.431 and 0.319,both P<0.05),while PGE2 was negatively correlated with MELD score(r=-0.412,P<0.05).The ROC curve analysis showed that HMGB1,sCD163,and PGE2 used alone had an area under the ROC curve(AUC)of 0.717,0.716,and 0.856,respectively,while the combination of the three indicators had the highest predictive value,with an AUC of 0.930,a sensitivity of 0.778,and a specificity of 0.920.Conclusion Serum HMGB1,sCD163,and PGE2 used alone or in combination have a good reference value in predicting the prognosis of HBV-ACLF patients,and the combination of the three indicators has the highest predictive value,which holds promise for further observation and research.

Acute-On-Chronic Liver FailurePrognosisHMGB1 ProteinSoluble CD163Prostaglandin E2

韩晨璐、梁海军、杨道坤、常海燕、魏帅、王新伟、高海丽

展开 >

新乡医学院第一附属医院感染内科,河南 新乡 453000

慢加急性肝功能衰竭 预后 HMGB1蛋白质 可溶性CD163 前列腺素E2

河南省医学科技攻关计划

LHGJ20210532

2024

临床肝胆病杂志
吉林大学

临床肝胆病杂志

CSTPCD北大核心
影响因子:1.428
ISSN:1001-5256
年,卷(期):2024.40(6)